Sort   by:  
 Page size 
UnknownCirculating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Not available
S-EPMC5815402 | biostudies-literature
UnknownSeven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Not available
S-EPMC5805480 | biostudies-literature
UnknownChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Not available
S-EPMC5891129 | biostudies-literature
UnknownPhase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
Not available
S-EPMC4879718 | biostudies-literature
UnknownTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Not available
S-EPMC4872347 | biostudies-literature
UnknownCDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Not available
S-EPMC7252221 | biostudies-literature
UnknownAssociation between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Not available
S-EPMC9839346 | biostudies-literature
UnknownDarolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Not available
S-EPMC9844551 | biostudies-literature
Sort   by:  
 Page size